Pacira Pharmaceuticals (PCRX) Receives Analyst Rating

Pacira Pharmaceuticals (PCRX) : 6 brokerage houses believe that Pacira Pharmaceuticals (PCRX) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Pacira Pharmaceuticals (PCRX). Zacks Investment Research suggests a Strong Buy with a rank of 1.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 1.67.

Pacira Pharmaceuticals (PCRX) : The highest level Pacira Pharmaceuticals (PCRX) is projected to reach is $109 for the short term and the lowest estimate is at $47. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $75.57 and the possibility the share price can swing is $18.98.


Also, Cowen & Company initiates coverage on Pacira Pharmaceuticals (NASDAQ:PCRX). The shares have now been rated Market Perform by the stock experts at the ratings house. The rating by the firm was issued on September 7, 2016.

Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened in the green at $40.78 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $40.78 and a low of $39.39 for the day. The stock did not find buyers even at the lows and closed at $40.54 recording a loss of -0.81%. 553,641 shares exchanged hands during the trading day. The stock had closed at $40.87 in the previous days trading.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.